Similar Items

Cover Image

Dulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial

Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exploratory analysis of the REWIND trial of t...

Full description

Saved in:
Bibliographic Details
Institution:Universidad EIA
Main Authors: Gerstein, Hertzel C., Colhoun, Helen M., Dagenais, Gilles R., Diaz, Rafael, Lakshmanan, Mark, Pais, Prem, Probstfield, Jeffrey, Riesmeyer, Jeffrey S., Riddle, Matthew C., Rydén, Lars, Xavier, Denis, Messan Atisso, Charles, Dyal, Leanne, Hall, Stephanie, Rao-Melacini, Purnima, Wong, Gloria, Avezum, Alvaro, Basile, Jan, Chung, Namsik, Conget, Ignacio, Cushman, William C., Franek, Edward, Hancu, Nicolae, Hanefeld, Markolf, Holt, Shaun, Jansky, Petr, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A., Lopez-Jaramillo, Patricio, Cardona-Munoz, Ernesto German, Pirags, Valdis, Pogosova, Nana, Raubenheimer, Peter J., Shaw, Jonathan E., Sheu, Wayne H-H., Temelkova-Kurktschiev, Theodora, The REWIND Investigators, Everest
Format: Artículo de revista
Language:English
Published: The Lancet 2019-07-13
Online Access:https://repositorio.udes.edu.co/handle/001/5693
Tags: Add Tag
No Tags, Be the first to tag this record!